All In Biotech

Free tool

FAERS Monitor: Ebanga

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761172 or its brand name (Ebanga, Ansuvimab-Zykl). Reports on generic versions are filed under their own applications.

Reports

3

Serious

3

100% of reports

Hospitalization

2

Death reported

2

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective for unapproved indication1
  • ebola disease1
  • foetal exposure during pregnancy1
  • low birth weight baby1
  • maternal exposure during pregnancy1
  • off label use1
  • postpartum haemorrhage1
  • premature baby1
  • premature delivery1

Reports by year received

View as table
YearReports
20242
20251

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,156 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
ebola disease1438628.282268.1103,206
postpartum haemorrhage15210.11050.61,301
low birth weight baby1882.4178.1220
premature delivery1440.388.9109
premature baby1233.047.057
drug ineffective for unapproved indication1127.825.831
foetal exposure during pregnancy186.317.421
maternal exposure during pregnancy178.715.919
off label use18.01.61

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.